Eli Lilly says it plans to apply for U.S. Food and Drug Administration (FDA) approval by the end of the year to market the ...

Stopping prescription weight loss drugs often leads to significant weight regain, according to a large-scale analysis of 11 ...

Weight-loss drugs significantly improve health, though they’re also tied to increased spending on other medical care that’s ...

Eli Lilly shares fell after the company’s oral drug showed less weight loss than hoped. It could still be huge.

In an 18-month clinical trial of the experimental GLP-1 pill orforglipron, about 60 percent of people lost at least 10 ...

In a clinical trial, the company's weight loss pill resulted in a nearly 12% weight loss at 72 weeks for participants who took the highest dose of the medication. On average, participants lost 7.8% to ...

Linda Yaccarino, a prominent figure in the media industry, has been appointed as the new CEO of EMed, a company focused on ...

GLP-1 drugs have shifted from medical to mainstream, and the impact is rippling far beyond health. From luxury to lifestyle, ...

Linda Yaccarino, former CEO of X (formerly Twitter) and ex-NBCUniversal ad exec, has reappeared as the CEO of eMed Population ...

Linda Yaccarino, the former X CEO who left the social media company last month in the wake of yet another Elon Musk ...

Yaccarino, who has a house in Woodbury, graduated from Deer Park High in 1981 with her twin sister, Lori. Both were elected ...

Even though Novo Nordisk warned that copycat versions of its obesity and diabetes drugs would hurt sales in the U.S., second-quarter sales saw a 67% rise year on year. More news covers telehealth ...